Skip to Content

CSL focused on creating medical breakthroughs

Fri 24 August 2018 09:20 AM Stocks to watch

Recent articles

Following the healthcare company’s FY 18 results, CSL’s Chief Financial Officer David Lamont and nabtrade’s Customer Insights Manager Vishal Teckchandani discuss:

  • Data insights on how nabtrade customers are investing in CSL,
  • Why investors should focus on the company's research & development activities,
  • If CSL has an appetite for a stock split, and
  • The CSL-112 trial, which is the largest trial undertaken by CSL for individuals who have suffered a heart attack. 

Note: The article referred to in the video can be viewed here.

 

redcape

Redcape Hotel Group - Dan Brady (RDC:ASX)

Redcape Hotel Group’s CEO Dan Brady tells us more about what they do and how they approach corporate social responsibility.

16 December 2019 Stocks to watch
wisr

Wisr - Anthony Nantes (WZR:ASX)

Wisr’s CEO Anthony Nantes shares what the company is about and how they plan to differentiate themselves.

16 December 2019 Stocks to watch
select-stock-idea

Select Harvests Limited - Brad Crump (SHV:ASX)

Select Harvest’s CFO Brad Crump tells us what consumption trends they’re observing and how the weather patterns may affect their almond crops.

16 December 2019 Stocks to watch
cMa

Centuria Metropolitan REIT - Grant Nicholas (CMA:ASX)

CMA’s CEO Grant Nichols tells us why they’ve repositioned themselves as a pure play, office REIT.

16 December 2019 Stocks to watch